Restenosis, the achilles' heel of coronary angioplasty

Pharmacotherapy

Volumn 18, Issue 5, 1998, Pages 1024-1040

  Wurdeman, Richard L ^a   Hilleman, Daniel E ^a   Mooss, Aryan N ^a  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; THROMBIN INHIBITOR;

CORONARY ARTERY OBSTRUCTION; GENE THERAPY; HEART MUSCLE REVASCULARIZATION; HUMAN; PATHOPHYSIOLOGY; RECURRENT DISEASE; REVIEW; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY; CORONARY DISEASE; CORONARY VESSELS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; STENTS;

EID: 0031711397     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Grüntzig AR, Senning A, Siegenthaler WE. Non-operative dilatation of coronary artery stenosis. N Engl J Med 1979;301:61-8.
2. Paranandi SN, Topol EJ. Contemporary clinical trials of restenosis. J Invasive Cardiol 1994;6(4):109-24.
3. Nobuyoshi M, Kiemura T, Nosaka H, et al. Restenosis after successful PTCA: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12(3):616-23.
4. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issues. In: Topol EJ, ed. Textbook of interventional cardiology, 2nd ed. Philadelphia: WB Saunders, 1994:15-35.
5. Topol EJ, Ellis SG, Cosgrove DM, et al. Analysis of coronary angioplasty practice in the United States with an insurance claims data base. Circulation 1993;87:1489-97.
6. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-74.
7. Schwartz RS, Murphy JG, Edwards WD, et al. Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. Circulation 1990;82:2190-200.
8. Asahara T, Bauters C, Pastore C, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995;91:2793-801.
9. Krasinski K, Spyridopoulos I, Asahara T, et al. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997;95:1768-72.
10. Rensing BJ, Hermans WR, Vos J, et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Circulation 1993;88:975-85.
11. Bourassa MG, Lespérance J, Eastwood C, et al. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1991;18:368-76.
12. FitzGerald GA. Dipyridamole. N Engl J Med 1987;316: 1247-57.
13. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76(1): 125-34.
14. Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;65:422-6.
15. Danchin N, Juillière Y, Kettani C, et al. Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty. Am Heart J 1994;127(3):494-8.
16. Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980;62:449-61.
17. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5-14.
18. American-Canadian Co-Operative Study Group. Persantine aspirin trial in cerebral ischemia. II. Endpoint results. Stroke 1985;16:406-15.
19. Chesebro JH, Webster MWI, Reeder GS, et al. Coronary angioplasty antiplatelet therapy reduces acute complications but no restenosis [abstr]. Circulation 1989;80(suppl II):II-64.
20. Schwartz L, Lesperance J, Bourassa MG, et al. The role of antiplatelet agents in modifying the extent of restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1990;119:232-6.
21. White CW, Knudson M, Schmidt D, et al. Neither ticlopidine nor aspirin-dipyridamole prevents restenosis post PTCA: results from a randomized placebo-controlled multicenter trial [abstr]. Circulation 1987;76(suppl IV):IV-213.
22. Schwartz L, Bourassa MG, Lespèrance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-19.
23. Bertrand ME, Allain H, Lablanche JM. Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA): the TACT study [abstr]. Circulation 1990;82(suppl III)):III-190.
24. Swanson KT, Vlietstra RE, Holmes DR, et al. Efficacy of adjunctive dextran during percutaneous transluminal coronary angioplasty. Am J Cardiol 1984;54(3):447-8.
25. Urban P, Buller N, Fox K, et al. Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty. Br Heart J 1988;60:485-8.
26. Thornton MA, Gruentzig AR, Hollman J, et al. Coumadin and aspirin in prevention of restenosis after transluminal coronary angioplasty: a randomized study. Circulation 1984;69:721-7.
27. Savage MP, Goldberg S, Bove AA, et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after coronary angioplasty. Multi-hospital eastern Atlantic restenosis trial (M-HEART II). Circulation 1995;92(11): 3194-200.
28. 2 receptor blockade. A randomized, double-blind, placebo-controlled trial. Circulation 1991;84:1568-81.
29. Knudtson ML, Flintoft VF, Roth DL, et al. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990;15:691-7.
30. Gershlick AH, Timmis AD, Rothman MT, et al. Postangioplasty prostacyclin does not reduce the frequency of restenosis [abstr]. Circulation 1990;82(suppl III):III-497.
31. Darius H, Nixdorff U, Zander J, et al. Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty. Agents Actions Suppl 1992;37:305-11.
32. Raizner AE, Hollman J, Abukhalil J, et al. Ciprostene for restenosis revisited: quantitative analysis of angiograms [abstr]. J Am Coll Cardiol 1993;21:321A.
33. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48(5):890-6.
34. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987;48:549-54.
35. Jang Y, Lincoff AM, Plow EF, et al. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994;24: 1591-601.
36. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb-IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
37. Pytela R, Pierschbacher MD, Ginsberg MH, et al. Platelet membrane glycoprotein IIb-IIIa: a member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986;231: 1559-62.
38. Cox D, Aoki T, Sekj J, et al. The pharmacology of the integrins. Med Res Rev 1994;14:195-228.
39. Phillips DR, Charo IF, Parisi LV, et al. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988;71: 831-43.
40. Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell 1991;65:359-62.
41. Ellis SG, Tcheng JT, Navetta FI, et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis 1993;4:167-75.
42. Tcheng JE, Ellis SG, Kleiman NS, et al. Outcome of patients treated with the GPIIb/IIIa inhibitor integrelin during coronary angioplasty: results of the IMPACT study [abstr]. Circulation 1993;88(suppl I):I-595.
43. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigators. N Engl J Med 1994;330:956-61.
44. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
45. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
46. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
47. Choi ET, Engel L, Callow AD, et al. Inhibition of neointimal hyperplasia by blocking alpha v, beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994;19:125-34.
48. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE investigators. Circulation 1997;96:1445-53.
49. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
50. Brack MJ, Simon R, Chauhan A, et al. The subcutaneous heparin and angioplasty prevention (SHARP) trial. J Am Coll Cardiol 1995;26:947-54.
51. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-9.
52. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-63.
53. Messmore HL, Wehrmacher WH. Therapeutic use of low molecular weight heparins. Semin Thromb Haemost 1993;19(suppl I):97-100.
54. Gravanis MB, Roubin GS. Histopathologic phenomena at the site of percutaneous transluminal angioplasty: the problem of restenosis. Hum Pathol 1989;20:477-85.
55. Currier JW, Pow TK, Haudenschild CC, et al. Low molecular weight heparin reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17(6, suppl B):118B-25.
56. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Circulation 1994;90:908-14.
57. Cairns JA, Gill J, Morton B, et al. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty; the EMPAR study. Circulation 1996;94:1553-60.
58. Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (Reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996;28:1437-43.
59. Currier JW, Pow TK, Minihan AC, et al. Colchicine inhibits restenosis after iliac angioplasty in the atherosclerotic rabbit [abstr]. Circulation 1989;80(suppl II):II-66.
60. Grines CL, Rizik D, Levine A, et al. Colchicine angioplasty restenosis trial (CART) [abstr]. Circulation 1991;84(suppl II):II-365.
61. O'Keefe JHJ, McCallister BD, Bateman TM, et al. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 1992;19: 1597-600.
62. Currier JW, Pow TK, Minihan AC, et al. Colchicine inhibits restenosis after iliac angioplasty in the atherosclerotic rabbit [abstr]. Circulation 1989;80(suppl II):II-66.
63. Berk BC, Gordon JB, Alexander RW. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J Am Coll Cardiol 1991;17(suppl III):111B-17.
64. Pepine CJ, Hirshfeld JW, MacDonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 1990;81:1753-61.
65. Stone GW, Rutherford BD, McConahay DR, et al. A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Cathet Cardiovasc Diagn 1989;18:227-31.
66. Okamoto S, Inden M, Setsuda M, et al. Effects of trapidil (triazolopyrimidine), a platelet derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1992;123: 1439-44.
67. Nishikawa H, Ono N, Notoyasu N, et al. Preventive effects of trapidil on restenosis after PTCA [abstr]. Circulation 1992;86(suppl I):I-53.
68. Clemmons DR, Van Wyk JJ. Evidence for a functional role of endogenously produced somatomedin-like peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J Clin Invest 1985;75:1914-18.
69. Bornfeldt KE, Arnqvist JH, Capron L. In vivo proliferation of vascular smooth muscle in relation to diabetes mellitus insulin-like growth factor I and insulin. Diabetologia 1992;35:104-8.
70. Jialal I, Crettaz M, Hachiya HL, et al. Characterization of the receptors for insulin and insulin-like growth factors on micro and microvascular tissues. Endocrinology 1985;117:1222-9.
71. Stiles CG, Capone GT, Schner CD, Antonidades HN, Van Wyk JJ, Pledger WJ. Dual control of cell growth by somatomedin and platelet-derived growth factor. Proc Natl Acad Sci USA 1979;76:1279-83.
72. Delafontaine P, Bernstein KE, Alexander RW. Insulin-like growth factor I gene expression in vascular cells. Hypertension 1991;17:693-9.
73. Howell M, Orskov H, Frystyk F, et al. Lanreotide, a somatostatin analogue, reduces insulin like growth factor I accumulation in proliferating aortic tissue in rabbits in vivo. Eur J Endocrinol 1994;130:422-5.
74. Kent KM, Williams DO, Cassagneau B, et al. Double-blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty [abstr]. Circulation 1993;88(suppl II):II-2725.
75. Eriksen UH, Amtorp O, Bagger JP, et al. Randomized double blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J 1995;130(1):1-8.
76. Emanuelsson H, Beatt KJ, Bagger JP, et al. Long term effects of angiopeptin treatment in coronary angioplasty. Circulation 1995;91(6):1689-96.
77. Serruys PW. Long term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis [letter]. Circulation 1995;92(9): 2759-60.
78. Serruys PW, Klein W, Tijssen JPE, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind, placebo-controlled trial. Circulation 1993;88:1588-91.
79. Gellman J, Ezekowitz MD, Sarembock IJ, et al. Effect of lovastatin on intimai hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:251-9.
80. Sahni R, Maniet AR, Voci G, Banka V. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991;121:1600-8.
81. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331(20):1331-7.
82. O'Keefe JH, Stone GW, McCallister BD, et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:649-52.
83. Gey FK, Puska P, Jourdon P, et al. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross cultural epidemiology. Am J Clin Nutr 1991;53:326-34.
84. Stampfer MJ, Hennekins CH, Manson JE, et al. Vitamin E consumption and the risk of coronary artery disease in women. N Engl J Med 1993;328:1444-9.
85. Rimm EB, Stampfer MJ, Ascheris A, et al. Vitamin E consumption and the risk of coronary artery disease in men. N Engl J Med 1993;328:1450-6.
86. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84: 5928-31.
87. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci USA 1987;84:7725-9.
88. Wilson RB, Middleton CC, Sun GY. Vitamin E, antioxidants and lipid peroxidation in experimental atherosclerosis of rabbits. J Nutr 1978;108:1858-67.
89. Parthasathy S, Young SG, Witztum JL, et al. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986;77:641-4.
90. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
91. Watanabe K, Sekiya M, Ikeda S, et al. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996;132:23-9.
92. Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the probucol angioplasty restenosis trial. J Am Coll Cardiol 1997;30:855-62.
93. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-72.
94. Ku G, Doherty NS, Wolos JA, et al. Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis. Am J Cardiol 1988;62:77B-81.
95. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994;75:181-9.
96. Unverdorben M, Kunkel B, Leucht M, Bachmann K. Reduction of restenosis after PTCA by diltiazem? [abstr]. Circulation 1992;86:I-53.
97. O'Keefe JH, Giorgi LV, Hartzler GO, et al. Effects of diltiazem on complications and restenosis after coronary angioplasty. Am J Cardiol 1991;67:373-6.
98. Circos T, David PR, Val PG, et al. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1985;109:926-31.
99. Whitworth HB, Roubin GS, Hollman J, et al. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1986;8:1271-6.
100. Hoberg E, Schwarz F, Schömig A, et al. Prevention of restenosis by verapamil: the verapamil angioplasty study (VAS) [abstr]. Circulation 1990;82:III-428.
101. Hillegass WB, Ohman EM, Leimberger JD, et al. A meta analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol 1994;73:835-9.
102. Ikeda Y, Kikuchi M, Toyama K, et al. Inhibition of human platelet functions by verapamil. Thromb Haemost 1981;45(2):158-61.
103. Kiyomoto A, Sasaki Y, Odawara A, Monta T. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites. Circ Res 1983;52(suppl I):I-115-19.
104. Mehta P, Mehta J, Ostrowski N, Brigmon L. Inhibitory effects of diltiazem on platelet activation caused by ionophore A23187 plus ADP or epinephrine in subthreshold concentrations. J Lab Clin Med 1983;102(3):332-9.
105. Powell J, Cloze J, Müller R, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8.
106. The MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 1992;86:100-10.
107. Faxon D, Aversano T, Barath P, et al. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 1995;25(2):362-9.
108. Desmet W, Vrolix M, De Scheerder I, et al. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation 1994;89:385-92.
109. Rakugi H, Wang D, Dzau V, Pratt R. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994;90: 449-55.
110. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A chain and c-myc gene expression by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-24.
111. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor-beta I expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-61.
112. Itoh H, Mukoyama M, Pratt RE, et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993;91:2268-74.
113. Farhy RD, Carretero OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointimal formation. Circ Res 1993;72(6):1202-10.
114. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994;251:143-50.
115. Gapinski JP, VanRuiswyk JV, Heudebert GR, Schectman GS. Preventing restenosis with fish oils following coronary angioplasty. A meta-analysis. Arch Intern Med 1993;152:1595-1601.
116. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90(5):2248-57.
117. Garrido A, Garrido F, Guerra R, et al. Ingestion of high doses of fish oil increases the susceptibility of cellular membranes to the induction of oxidative stress. Lipids 1989;24:833-5.
118. Meydani M, Natiello F, Goldin B, et al. Effect of long-term fish oil supplementation on vitamin E status and lipid peroxidation in women. J Nutr 1991;121:484-91.
119. Hu ML, Frankel EN, Leibovitz BE, et al. Effect of dietary lipids and vitamin E on in vitro lipid peroxidation in rat liver and kidney homogenates. J Nutr 1989;119:1574-82.
120. Hu ML, Frankel EN, Tappel AL. Effect of dietary menhaden oil and vitamin E on in vivo lipid peroxidation induced by iron. Lipids 1990;25:194-8.
121. Lenz PH, Watkins T, Bierenbaum M. Effect of dietary menhaden, canola and partially hydrogenated soy oil supplemented with vitamin E upon plasma lipids and platelet aggregation. Thromb Res 1991;61:213-24.
122. Brown JE, Wahle KW. Effect of fish-oil and vitamin E supplementation on lipid peroxidation and whole-blood aggregation in man. Clin Chim Acta 1990;193:147-56.
123. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-6.
124. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
125. Serruys PW, Emanuelsson H, van der Giessen W, et al. Heparin coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the BENESTENT-II pilot study. Circulation 1996;93(3):412-22.
126. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
127. Cohen DJ, Krumholz HM, Sukin CA, et al. In-hospital and one year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Circulation 1995;92:2480-7.
128. Kimura T, Hiroyoshi Y, Nakagawa Y, et al. Three year follow-up after implantation of metallic coronary artery stents. N Engl J Med 1996;334:561-6.
129. Hehrlein C, Gollan C, Donges K, et al. Low-dose radioactive endovascular stents prevent smooth muscle cell proliferation and neointimal hyperplasia in rabbits. Circulation 1995;92:1570-5.
130. Fischell TA, Kharma BK, Fischell DR, et al. Low-dose β-particle emission from "stent" wire results in complete, localized inhibition of smooth muscle cell proliferation. Circulation 1994;90:2956-63.
131. Tierstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-703.
132. Condado JA, Furdiel O, Espinoza R, et al. Endovascular irradiation for avoidance or recurrent stenosis after stent implantation in peripheral arteries. A 5 year follow-up [abstr]. Discoveries in Radiation for Restenosis 1996;11-12:105.
133. Simons M, Edelman ER, Dekeyser R, et al. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
134. Bennett MR, Anglin S, McEwan R, et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994;93:820-8.
135. Morishita R, Gibbons GH, Ellison K, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993;90:8474-8.
136. Morishita R, Gibbons GH, Ellison K, et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J Clin Invest 1994;93:1458-64.
137. Maruyama I, Shigeta K, Miyahara H, et al. Thrombin activates NF-kappa B through thrombin receptor and results in proliferation of vascular smooth muscle cells: role of thrombin in atherosclerosis and restenosis. Ann NY Acad Sci 1997;811:429-36.
138. Mehta VY, Jorgensen MB, Raizner AE, et al. Spontaneous regression of restenosis: an angiographic study. J Am Coll Cardiol 1995;26:696-502.